DRA

Torrent Pharma owes its success in the domestic market to its thrust on frontline research, strategic marketing and world-class manufacturing. It is among the largest spenders on R&D and has set up one of the most advanced research centers in the country at an investment of Rs. 200 crores so far. It has discovered and patented the AGE (Advanced Glycosylation End Product) Breaker Compound which has potential to treat heart diseases and diabetes related vascular complications.